Risks of Sulpiride-Induced Parkinsonism in Peptic Ulcer and Gastroesophageal Reflux Disease Patients in Taiwan: A Nationwide Population-Based Study.
drug-induced parkinsonism
gastroesophageal reflux disease
peptic ulcer disease
population-based study
sulpiride
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
12
2019
accepted:
20
03
2020
entrez:
12
5
2020
pubmed:
12
5
2020
medline:
12
5
2020
Statut:
epublish
Résumé
Sulpiride is a highly selective dopamine D2 receptor antagonist and is commonly used in psychiatric disorders, Tourette syndrome, peptic ulcer disease (PUD), and gastroesophageal reflux disease (GERD). However, sulpiride has been recognized as a potential cause of drug-induced parkinsonism (DIP) for a long time. In this study, we aimed to focus on analysis of sulpiride-induced parkinsonism (SIP) in PUD and GERD patients based on a nationwide population. Data were obtained from the Taiwan's National Health Insurance Research Database. The study enrolled 5,275 PUD or GERD patients, of whom were divided into two groups, based on their exposure (1,055 cases) or non-exposure (4,220 cases) to sulpiride. During the study period (2000-2012), the incidence rate of parkinsonism was 261.5 and 762.2 per 100,000 person-years in the control and sulpiride-treated groups, respectively. For patients with at least 14 days of prescription for sulpiride, the adjusted hazard ratio (aHR) was 2.89, 95% confidence interval (CI): 2.04-4.11. Patients with age more than 65 years (aHR = 4.99, 95% CI = 2.58-9.65), hypertension (aHR = 2.39, 95% CI = 1.49-3.82), depression (aHR = 2.00, 95% CI = 1.38-2.91), and anxiety (aHR = 1.45, 95% CI = 1.01-2.09) had significant higher risk of developing parkinsonism. An average annual cumulative sulpiride dose > 1,103 mg was accompanied by the greatest risk of SIP; sulpiride use for ≥ 9 days is a cut-off point for predicting future SIP. At the population level, sulpiride may be frequently prescribed and apparently effective for PUD and GERD. SIP is associated with older age, hypertension, depression or anxiety comorbidities. Physicians should be aware of the neurogenic adverse effects, even when the drug is only used in low-dose or a short duration.
Sections du résumé
BACKGROUND
BACKGROUND
Sulpiride is a highly selective dopamine D2 receptor antagonist and is commonly used in psychiatric disorders, Tourette syndrome, peptic ulcer disease (PUD), and gastroesophageal reflux disease (GERD). However, sulpiride has been recognized as a potential cause of drug-induced parkinsonism (DIP) for a long time. In this study, we aimed to focus on analysis of sulpiride-induced parkinsonism (SIP) in PUD and GERD patients based on a nationwide population.
METHODS
METHODS
Data were obtained from the Taiwan's National Health Insurance Research Database. The study enrolled 5,275 PUD or GERD patients, of whom were divided into two groups, based on their exposure (1,055 cases) or non-exposure (4,220 cases) to sulpiride.
RESULTS
RESULTS
During the study period (2000-2012), the incidence rate of parkinsonism was 261.5 and 762.2 per 100,000 person-years in the control and sulpiride-treated groups, respectively. For patients with at least 14 days of prescription for sulpiride, the adjusted hazard ratio (aHR) was 2.89, 95% confidence interval (CI): 2.04-4.11. Patients with age more than 65 years (aHR = 4.99, 95% CI = 2.58-9.65), hypertension (aHR = 2.39, 95% CI = 1.49-3.82), depression (aHR = 2.00, 95% CI = 1.38-2.91), and anxiety (aHR = 1.45, 95% CI = 1.01-2.09) had significant higher risk of developing parkinsonism. An average annual cumulative sulpiride dose > 1,103 mg was accompanied by the greatest risk of SIP; sulpiride use for ≥ 9 days is a cut-off point for predicting future SIP.
CONCLUSION
CONCLUSIONS
At the population level, sulpiride may be frequently prescribed and apparently effective for PUD and GERD. SIP is associated with older age, hypertension, depression or anxiety comorbidities. Physicians should be aware of the neurogenic adverse effects, even when the drug is only used in low-dose or a short duration.
Identifiants
pubmed: 32390831
doi: 10.3389/fphar.2020.00433
pmc: PMC7193075
doi:
Types de publication
Journal Article
Langues
eng
Pagination
433Informations de copyright
Copyright © 2020 Wei, Tzeng, Lin, Yeh, Hsu and Kung.
Références
J Neurogastroenterol Motil. 2018 Oct 1;24(4):593-602
pubmed: 30347938
PLoS One. 2014 Feb 27;9(2):e89795
pubmed: 24587038
BMC Public Health. 2019 Oct 22;19(1):1328
pubmed: 31640652
Br J Psychiatry. 1985 Sep;147:283-8
pubmed: 3904885
Agents Actions. 1994 Oct;42(3-4):149-53
pubmed: 7879701
Adv Biochem Psychopharmacol. 1982;35:109-41
pubmed: 6756059
Ther Adv Neurol Disord. 2011 Jan;4(1):25-45
pubmed: 21339906
Pharmacol Res. 1995 Feb;31(2):95-101
pubmed: 7596960
J Gastroenterol. 2016 Mar;51(3):177-94
pubmed: 26879862
Gut. 1986 Dec;27(12):1512-5
pubmed: 3804028
Ann Pharmacother. 2019 Nov;53(11):1102-1110
pubmed: 31216861
Lancet. 2017 Dec 17;388(10063):3048-3059
pubmed: 27349358
J Int Med Res. 2001 Jul-Aug;29(4):304-13
pubmed: 11675904
Lancet. 2017 Aug 5;390(10094):613-624
pubmed: 28242110
Psychopharmacology (Berl). 1983;81(3):258-60
pubmed: 6417717
Lancet. 1977 Dec 24-31;2(8052-8053):1367-8
pubmed: 74783
Can J Psychiatry. 2018 Jan 1;:706743718777392
pubmed: 29758999
Front Psychiatry. 2019 Jan 18;9:723
pubmed: 30713507
J Clin Neurol. 2012 Mar;8(1):15-21
pubmed: 22523509
J Psychopharmacol. 1993 Jan;7(3):290-2
pubmed: 22290844
Igaku Kenkyu. 1993 Feb;63(1):15-9
pubmed: 8328259
Gastroenterology. 1979 Feb;76(2):315-22
pubmed: 365665
Gastroenterology. 1978 Feb;74(2 Pt 1):221-3
pubmed: 563826
Yonsei Med J. 2019 Aug;60(8):760-767
pubmed: 31347331
Gen Hosp Psychiatry. 2014 Jan-Feb;36(1):63-7
pubmed: 24120385
PLoS One. 2012;7(12):e51148
pubmed: 23251441
Front Psychol. 2019 Mar 13;10:284
pubmed: 30918490
Drug Saf. 1996 May;14(5):288-98
pubmed: 8800626
Psychiatry Clin Neurosci. 2019 Aug;73(8):501-507
pubmed: 31077503
J Gastroenterol. 2016 Aug;51(8):751-67
pubmed: 27325300
Clin Gastroenterol Hepatol. 2015 Mar;13(3):498-506.e1
pubmed: 25111233
Mov Disord. 2017 Feb;32(2):227-234
pubmed: 27779780
Ann Pharmacother. 1995 Feb;29(2):152-60
pubmed: 7756714
Drugs Exp Clin Res. 1991;17(6):317-21
pubmed: 1769321
Acta Psychiatr Scand. 1989 Jul;80(1):92-6
pubmed: 2669445
J Neurogastroenterol Motil. 2018 Oct 1;24(4):559-569
pubmed: 30347935